INTRODUCTION
Immunophenotyping, as the process of identifying discrete patient immune cell phenotypes, has gained prominent traction in areas such as HIV and leukemia research where perturbations in immune cell homeostasis directly reflect disease pathogenesis and correlate with patient prognosis. [1] [2] [3] Using flow cytometry, immune cell surface markers with bimodal distributions (which are either negative or positive in expression) allow unambiguous discrimination of immune cell profiles that correlate with clinical outcome, such as the presence CD8
þ INF-g þ double-positive cells in HIV patients and CD38
þ peripheral blood cells in B-cell chronic lymphocytic leukemia patients. 1, 2 A potentially valuable yet underutilized area for lung disease immunophenotyping lies in the study of human alveolar macrophages (AMFs), which are the predominant immune cells within the alveolar airspaces. However, apart from the utilization of CD14 and CD16 to discern between classical CD14 þ CD16 À and patrolling CD14 high Gr-1 À counterparts in mice), 4 few macrophage (MF) surface markers exist in a convenient bimodal distribution pattern for disease-based characterization. Few are also identically expressed between mice and men. 5 This suggests two possibilities: that more translatable MF markers remain to be identified or there is an abundance of surface markers with continuous distributions that have rendered themselves inappropriate for traditional immunophenotyping. Considering the depth of study in the field of MF heterogeneity, the latter appears as the most likely option.
Over the past few years, personalized therapy of human lung diseases has been greatly advanced by the concept of disease endotypes, which links clinically observed phenotypes to underlying molecular mechanisms. 6 Endotyping asthma has successfully identified discrete patient subgroups who share a similar disease progression or treatment response, 7 reorganizing patient management through the implementation of more personalized treatment strategies. This asks whether a similar approach can be applied to chronic obstructive pulmonary disease (COPD), which is mechanistically heterogeneous and involves high patient symptom burdens, which manifest independently of severe lung function decline. 8, 9 In particular, recent reports of a hyper-inflammatory COPD patient subgroup with increased disease mortality and acute lung exacerbations risk suggest that inflammatory and non-inflammatory disease endotypes may exist in COPD. 9, 10 This concept is emphasized by the existence of both immune and nonimmune driven mechanisms of emphysema induction in mice. [11] [12] [13] Interestingly, in mice, deletion of Src homology 2 domain-containing 5' inositol phosphatase-1 (Inpp5d or SHIP-1; a negative regulator of growth factor receptor-mediated myeloid cell activation and survival) or constitutive activation of Hematopoietic cell kinase (Hck; a Src-family kinase abundant in myelomonocytic cells) both lead to the spontaneous development of chronic inflammatory lung disease sharing features of human COPD. SHIP-1 À / À mice develop AMF-driven chronic lung inflammation, severe emphysema, [14] [15] [16] [17] [18] and COPD co-morbidities, such as wasting, osteoporosis and an increased susceptibility to bacterial infections. [19] [20] [21] Hck F/F gain-of-function mice, generated by a tyrosine to phenylalanine substitution (Y499F) in the regulatory domain which prevents Hck inactivation, develop airway mucus metaplasia and mild emphysema characterized by chronic eosinophilic and monocytic lung inflammation and are hypersensitive to lipopolysaccharide (LPS). 22 Further study of SHIP-1
and Hck F/F mouse models may thus help refine the search for hyper-inflammatory COPD endotypes.
To facilitate the discovery of parallel lung immunophenotypes between mice and humans, we devised a new and internally standardized approach using flow cytometry that focuses on AMFs and other innate immune cell subpopulations as defects in these cell types are linked to asthma, COPD, and recurrent bacterial and viral chest infections. This easily adoptable approach compares CD11b expression levels on AMFs with anchor CD11b expression levels in blood neutrophils and additionally identifies CD11b AMF upregulation as a hallmark of acute lung exacerbations in SHIP-1 À / À mice. Overall, our study incorporates AMF phenotyping with other preexisting parameters for clinical endotyping (the presence of eosinophilia or neutrophilia) to demonstrate that innate lung immunophenotypes exist heterogeneously in both mouse models of chronic inflammatory lung disease and human patients.
RESULTS

Identification of distinct inflammatory immune cell profiles in mouse lungs
We and others have previously identified residential AMF CD11b upregulation as a marker of acute and chronic lung inflammation in mice. 15, 23 Residential AMFs are CD11b neg in healthy adult mouse lungs at homeostasis. Under selective inflammatory conditions, CD11b expression is upregulated and differential CD11b pos AMF proportions can distinguish between the peak and resolution of acute lung inflammation, respectively. 15 This scenario (either an absence or presence of inflammation-associated CD11b pos AMFs) is ideal for immunophenotyping as binary CD11b expression negates interpretation ambiguities and excessive standardization procedures. In translating this to human patient samples, however, we discovered that CD11b was basally expressed on all human AMFs but varied noticeably between individual patients ( Figure 1a) . As MF markers rarely directly translate between man and mouse, we screened for other putative M^activation markers such as CD14, CD86, major histocompatibility complex (MHC) Class II, CD124, CD206, Toll-like receptor (TLR)-2, and TLR-4 but observed consistently high or low surface expression levels (data not shown).
This led us to postulate that human AM^surface markers (including CD11b) are generally continuous rather than bimodal in distribution, especially as human AMFs are under constant exposure to a diverse repertoire of inhaled insults and environmental antigens. Unfortunately, flow cytometry measurement of markers with a continuous distribution loses quantitative meaning outside single experiments as expression is presented as a mean fluorescence intensity (MFI), a value which changes with cell autofluorescence, antibody (Ab) signal strength, and laser voltage settings. As MFI values are relative, large-scale clinical usage becomes limited even with single peak autofluorescent bead set-ups, as bead values still fluctuate within a small range between experiments and may diminish over time, hampering diagnostic accuracy. Thus, with continuous AM^CD11b expression as our marker of interest, we explored whether alternative analytical methods could still detect distinct lung immune cell profiles in both mice and humans using flow cytometry. To do this, we re-examined established mouse models of acute and chronic lung inflammation for potential internal anchors of AMF CD11b expression (gating strategy in Supplementary  Figure S1 online).
We observed that blood neutrophil CD11b expression was surprisingly constant between phosphate-buffered saline (PBS) vehicle and LPS-challenged or Mem71 influenza virus-infected mice independent of lung pathology ( Figure 1b and Supplementary Table S1 online). Similarly, we found that blood neutrophil CD11b expression remained constant in mice that spontaneously Figure 1c and Supplementary Table S1 online). In acute lung challenge studies, day 3 post-LPS challenge and day 10 post-influenza virus infection were chosen as they represent the peak of acute lung inflammation and initiation of disease resolution after virus is cleared, respectively, in these two different inflammatory conditions. In contrast to Mem71 infection, resolution at day 10 post-LPS challenge is characterized by a restoration to the homeostatic CD11b neg AM^phenotype. 15 In mice, blood neutrophils were CD11b pos with a staining intensity between the expression range of CD11b neg and CD11b high CD11c high AM^s, providing an internal reference point to which AM^CD11b expression could be compared (Figure 1b,c) . This approach negates influences from Ab signal strength and laser voltage settings on MFI level, as the ratio of AM^to blood neutrophil CD11b expression remains internally constant (see Supplementary Figure S2a and Supplementary Figure S2b ,c and Supplementary Table S1 online). 16, 17, 22 Increased AM^to blood neutrophil CD11b expression profiles were also observed for increasing LPS doses at day 3 post-challenge in C57BL/6 mice (see Supplementary Figure  S2d Identification of new immune cell parameters associated with acute lung exacerbations Acute exacerbations of COPD classically involve increased neutrophil recruitment and pro-inflammatory cytokine production, 25, 26 although eosinophils have also been increasingly linked to exacerbation predisposition. 27 However, it remains unknown how conserved or heterogeneous this inflammatory milieu is between affected patients. SHIP-1 À / À and Hck F/F mice have spontaneous inflammatory and emphysematous phenotypes that resemble patterns observed in human COPD. 16, 17, 22 To test whether specific BAL profiles could also be discerned during COPD-like acute lung exacerbations, SHIP-1 À / À and Hck F/F mice were challenged with a single intranasal dose of LPS. LPS-challenged SHIP-1 À / À and Hck Altogether, these results demonstrate that increased CD11b AMF expression is a mouse marker of active lung inflammation with differential patterns of AMF CD11b upregulation and eosinophil, neutrophil, or monocyte recruitment present in acute and chronic inflammatory lung conditions as well as COPD acute exacerbation models.
In vivo targeting of CD11b pos lung macrophages
CD11b is ubiquitously expressed on monocytes and neutrophils, which prevents the exclusive targeting of AMFs using anti-CD11b mAbs. However, as CD11b is discretely expressed on inflammatory AMFs in mice, we used antiCD11b administration to test whether CD11b pos AMFs could be selectively blocked without perturbations to homeostatic Decreased lung tissue apoptosis was observed in the lungs of anti-CD11b Ab-treated, but not vehicle-PBS or rat IgG isotype control Ab-treated C57BL/6 mice at day 3 post-LPS challenge (Figure 4h,i) . In contrast, CD11b
À / À mice did not show attenuated neutrophil or monocyte recruitment day 3 post-LPS challenge but did show variable AMF and monocyte CD11a expression and upregulated monocyte CD11c surface expression (see Supplementary Figure S5 online).
Identification of analogous human immune cell profiles
As distinct BAL cell immunophenotypes were clearly discerned in mice, we investigated whether parallel immune cell features could be identified in humans. Blood neutrophil CD11b expression was similar between healthy volunteers and respiratory patients seen in the day clinic, although CD11b variation is higher in humans than in mice (Figure 5a) . Nevertheless, 492% of all patient blood neutrophils existed within the same gated CD11b expression range used to reference AMF CD11b expression (see Supplementary Figure S6a ,b online). AM^to blood neutrophil CD11b expression clearly distinguished between individual patients with lower or higher AM^CD11b expression analyzed on the same day independently of data acquisition variations (Figure 5b ). AM^CD11b upregulation could also be confirmed by a comparison of AM^CD11b and CD14 expression levels and standard AM^CD11b MFI calculations ( Figure 5c ; MFI: 101 and 270 for CD11b expression on PT4912A and PT4912B, respectively).
For human BAL cell immunophenotyping, CD33 was chosen over CD11c as CD33 is a commonly used pan MF marker in humans, 28 which separated AMFs more clearly than CD11c in our studies and thus is a more definitive marker of human AMFs (see Supplementary Figure S7a immunophenotyping, could simultaneously be measured as the proportion of granular CD15 high CD11b high cells in BAL (see Supplementary Figure S1 online and Figure 6a- (Figure 6a-d) . Surprisingly, this mirrored the distinct immunophenotypes observed in C57BL/6 compared with SHIP-1 À / À and Hck F/F mice. Patients with CD11b low AMFs (set as having p10% AMFs with higher CD11b expression than blood neutrophils) showed low neutrophil and monocyte infiltration and most closely (Figure 6d) . Interestingly, a unique subset of CD33 high CD11b low non-lymphocyte cells was additionally found in the BAL of PT5012 (Figure 6d) . These atypical myeloid cells were lobe-specific to disease pathology (see Supplementary Figure S8 online).
As human AMF CD11b expression exists in a continuum, larger-scale clinical studies are required to identify CD11b high AMF cutoffs, which correlate with increased lung or systematic inflammation and disease burden. Our results demonstrate that patients with CD11b low or CD11b high AMFs exist and can be identified in a directly comparable manner. To represent AMF CD11b expression in an unbiased manner, we additionally calculated AMF CD11b MFIs and AMF to blood neutrophil CD11b MFI ratios for each patient (Figure 6a-d and Supplementary Table S2 online). MFI values fluctuate between individual experiments even with the usage of single peak fluorescent beads. However, patients categorized into the subgroups A and C were clearly distinguished by all calculation parameters (see Supplementary Table S2 online). As additional confirmation of CD11b selective AMF expression heterogeneity, we simultaneously measured AMF CD14 expression in the same experiment. In contrast to CD11b, CD14 AMF surface expression remained relatively constant between individual patients independently of AMF CD11b expression differences or lung disease status (Figure 6a-d) . Moreover, while blood neutrophil CD11b expression was relatively constant between patients, blood vs. lung neutrophil CD11b upregulation was observed in LPS-challenged C57BL/6 mice, SHIP-1 À / À and Hck F/F mice and human patients with similar inflammatory BAL cell profiles (see Supplementary Figure S9a ,b online). The degree of blood vs. lung neutrophil CD11b upregulation positively correlated with AMF CD11b upregulation (r ¼ 0.806) and further distinguished between patients with CD11b low or CD11b mod/high AMFs, providing an additional parameter of local lung inflammation (see Supplementary  Figure S9b online).
DISCUSSION
Our study describes a simplified and internally standardized flow cytometry approach for human lung immunophenotyping, adapted from the study of inflammatory lung conditions in mice. Critically, it is the first approach that can systematically profile AMF-based alterations alongside preexisting immune cell parameters in a directly comparable manner. AMFs are the predominant immune cell population within the lung parenchyma and express an expansive repertoire of cell surface molecules, which dynamically reorganize in response to different environmental stimuli. 29 Theoretically, this should render them as more selective reporters of the inflammatory microenvironment compared with current parameters such as lung neutrophilia or eosinophilia, which only indicate immune subset presence and not phenotype.
In truth, however, there are very few disease-associated MF markers in humans or even mice. The first reason stems from their dynamic and expansive nature; MFs activate a spectrum of transcriptional programs in response to a diverse array of environmental stimuli in a time-dependent manner. 30 This creates confusion in the absence of common descriptive standards as different studies ascribing markers to different MF activation states may not actually match each other. 5 For instance, induced nitric oxide synthase and Arginase I expression have been extensively used to discriminate between more classically M(LPS or interferon-g) or alternatively M(interleukin-4) activated MFs yet their presence is confounded by mouse strain-specific differences in enzyme expression and species-dependent differences in arginine and nitric oxide generation. 31, 32 Recently, transcriptome studies of tissue MF and dendritic cell subsets and differentially stimulated human monocyte-derived MFs have identified new genes with selective expression in different tissue MF subsets or activation stimuli (such as vascular cell adhesion molecule 1 for splenic MFs, intercellular adhesion molecule-2 for peritoneal MFs, Siglec H for microglial). 30, [33] [34] [35] This unbiased and systematic approach may generate new disease-specific MF markers for further evaluation and renders the discovery of systematic human MF profiling methods an even more critical objective.
A second obstacle lies in the difficulty of translating candidate MF markers from animal or in vitro studies. Few surface markers are similarly expressed on mouse and human AMFs. Translatable MF activation markers are so far limited to several chemokines, scavenger receptors, and matrix proteins. 5 As the only cell surface receptors from the list, scavenger receptors are the most pragmatic candidates for immunophenotyping. However, apart from MARCO, 36 few scavenger receptors are even dually expressed on mouse and human AMFs, let alone in parallel stimuli-selective patterns. More importantly, the expression of these and many other classes of MF surface proteins is predominantly continuous. 37, 38 Continuously expressed markers are represented as MFIs, which permits semi-quantitative comparisons within single flow cytometry experiments but hinders comparisons and data replication between independent studies. MFIs also do not provide information about cell population spread, may be altered by different gating strategies, and can be inadvertently skewed by extremely low or high value false events captured, future questioning their usefulness as meaningful clinical readouts. Thus, without alternative study strategies, many future candidate human MF markers may be rejected in the screening process in favor of binary observations, which are biologically unlikely. A conventional myeloid cell parameter would be the frequency of CD14 pos CD16 neg pro-inflammatory monocytes, CD14 pos CD16 pos vs. CD14 low CD16 pos patrolling monocytes in individual patients, 39 which can be used to describe the local environment in terms of recruited monocyte phenotypes. However, residential MFs possess different and often opposing functions to recruited monocytes and an understanding of residential MF responses may provide a more accurate reflection of the local inflammatory state. Using our flow cytometry approach, we show that AMF CD11b upregulation occurs in both mice and human patients alongside other inflammatory changes despite basal CD11b expression on human AMFs. In particular, our studies suggest that CD11b high AMFs may identify an important subset of patients with inflammatory lung conditions and that a combinational immunophenotyping approach that monitors AMF CD11b expression alongside the absence or presence of other innate immune cell subsets may provide a more personalized understanding of individual patient lung microenvironments.
CD11b is a leukocyte integrin composed of the CD11b a subunit and common integrin b2 subunit and binds to ligands intercellular adhesion molecule-1, iC3b (cleaved product of complement 3b), and fibrinogen. 40 CD11b function was first suggested when a deficiency in the common integrin b2 subunit (and hence LFA-1, CD11b, and p150/95 assembly and surface expression) was identified in a group of patients with recurrent bacterial infections owing to defective neutrophil and myeloid cell adhesion and phagocytosis. 41 Later studies identified CD11b upregulation as a functional component of neutrophil aggregation but not neutrophil endothelial cell adhesion or extravasation.
42 Surprisingly, global CD11b deletion in mice does not induce prominent physiological alterations or attenuate neutrophil accumulation in inflamed tissues. 43, 44 In CD11b À / À mice, however, complement-mediated phagocytosis and vasculitis are significantly attenuated, 43, 44 most likely through a failure of iC3b ligand-mediated activation of CD11b receptor signaling. From our studies, given that antiCD11b Ab administration but not CD11b deletion attenuated lung inflammation in mice, global CD11b deletion may not replicate the consequences of transiently targeting CD11b in chronic diseases. As blocking of surface AM^CD11b rather than depletion of CD11b pos AM^s most likely occurred following anti-CD11b Ab administration, it is crucial to dissect whether AM^CD11b signaling itself or CD11b pos/high AM^s are potential effectors of acute and chronic lung inflammation. Specifically, the comparison of CD11b neg (or CD11b low in humans) and CD11b pos/high AM^transcriptomes may identify whether alterations in CD11b-related signaling pathways or a broader array of effector pathways exist between these two AM^subpopulations.
AM^CD11b expression alterations have been previously described in clinical studies of acute and chronic inflammatory lung diseases. CD11b high AM^s correlated with increased lung monocyte influx and respiratory failure severity in a 21-day follow-up of ARDS patients requiring mechanical ventilation. 45 AM^CD11b upregulation was also observed in patients with pneumonia compared with healthy volunteers in a separate study that correlated CD11b AM^expression with the level of neutrophil chemokine interleukin-8. 46 Interestingly, AM^CD11b expression was not significantly different between COPD patients and healthy non-smokers in a previous study, though this may reflect a recruitment of inflammatory vs. non-inflammatory COPD endotypes. 47 Overall, the current diversity of CD11b AM^-and lung eosinophil-associated mouse models of emphysema temptingly suggests that distinct lung innate immune cell niches may be present in different COPD endotypes. Lung immunophenotyping in previously established COPD animal models may also help the field to more clearly differentiate immune-vs. non-immune-driven mechanisms of human COPD pathogenesis. 48 Although our approach can be immediately used in any flow cytometer facility, small caveats remain that apply to all lung immunophenotyping studies. Sample storage needs to be consistent for large-scale usage. 49 We used freshly obtained BAL samples for our studies in order to match the in vivo immunophenotype as closely as possible. This may be difficult in places where same-day flow cytometry analysis is not possible and cryopreservation options have to be explored. Cigarette smoke-induced cell autofluorescence is also a major obstacle as background AMF signals are exponentially increased in current smokers, confounding fluorescence AMF read-outs. Current cigarette smokers (o6 months) were excluded from our study, but this may be undesirable for COPD endotyping. In unavoidable scenarios, it is possible that non-fluorescence detection methods such as mass cytometry may be employed to characterize all samples from a similar baseline, although non-specific Ab-binding issues may still exist.
In summary, our study introduces a new internally standardized and hence directly comparable approach for AMF immunophenotyping. Used in combination with other established parameters for clinical endotyping (the presence of eosinophilia or neutrophilia), we show that inflammationassociated CD11b AMF profiles exist heterogeneously in both mouse lung disease models and human patients. This is timely as our understanding of immune cell contributions to disease pathogenesis and disease endotyping advances and the technology to discriminate differential immune cell subsets becomes more widely accessible.
METHODS
Study approval. Recruited patients undergoing a bronchoscopy for clinical diagnosis participated voluntarily and provided informed consent under protocols approved by the Melbourne Health Institutional review board. Written informed consent was obtained from all subjects prior to inclusion.
Human study subjects. Non-targeted or peri-lesion BAL were performed depending on computed tomographic scan presentations using 3 Â 20 ml saline, and patient BAL cells were collected for fluorescence-activated cell sorting (FACS) analysis. Three milliliters of blood was also collected from each patient. Patient diagnosis was established by same-day tissue biopsy (see Supplementary Table S3 online). A total of 14 patient samples were analyzed with standardized machine settings using fluorescent beads (allophycocyanin (APC) and APC-Cy7 fluorescence reference standards, Bangs Laboratories, Fishers, IN). Patients with BAL samples showing highly autofluorescent AMFs owing to recent cigarette smoke exposure were excluded from analysis as elevated autofluorescence greatly masks the surface expression of markers in AMFs.
Mice. SHIP-1 À / À 16 and Hck F/F 22 mice have been described and were crossed onto the C57BL/6 background for X7 generations. C57BL/6 CD11b À / À mice were a gift from Professor Karlheinz Peter (Baker IDI Heart and Diabetes Institute, Melbourne, Australia). C57BL/6 mice were purchased from the Monash Animal Services (ARL, Melbourne, Australia). All mice were kept in specific pathogen-free conditions (Monash MARP and MICU, Melbourne, Australia). All animal experiments were approved by the Alfred Medical Research and Education Precinct (AMREP) Animal Ethics Committee in accordance with National Health and Medical Research Council (NHMRC) Australia guidelines.
LPS challenge. Eight-12-week-old C57BL/6, CD11b
À / À , SHIP-1 À / À , or Hck F/F mice were lightly anesthetized with 5% isofluorane and intranasally administered 30 ml of Escherichia coli LPS (10 mg per mouse, serotype O114:B4; Sigma, Saint Louis, MO). LPS-challenged mice were euthanized at day 3 post-LPS challenge. Vehicle control C57BL/6 mice received 30 ml of Dulbecco's modified Eagle's medium.
Mem71 infection. Eight-12-week-old C57BL/6 mice were lightly anesthetized and intranasally delivered 30 ml Mem71 influenza virus (31,000 pfu per mouse, sublethal dose). Mice were euthanized at day 10 postinfection.
Antibody treatment. Twenty-four hours post-LPS challenge, C57BL/6 mice were lightly anesthetized and intranasally administered 30 ml of anti-CD11b antibody (1.0, 0.5 or 0.1 mg kg À 1 , clone M1/70, Bio X cell, West Lebanon, NH) or rat IgG isotype control (1 mg kg À 1 , clone LTF-2, Bio X cell). Mice were euthanized on day 3. Ab administration occurred at 24 h post-LPS as this marks the onset of AM^Mac-1 upregulation 15 and minimizes the neutralization of CD11b high lung neutrophils recruited earlier.
Flow cytometry. For mouse BAL, filtered BAL and red blood celllysed blood cells were resuspended in FACS buffer (Mouse PBS, 2% fetal calf serum, 2 mM EDTA) and incubated with Fc block (0.6 mg ml À 1 , anti-mouse CD32/CD16, clone 2.4G2, 10 min). Cells were stained with 11 monoclonal Abs or non-binding Ab controls (20 min, 4 1C on ice, listed in Supplementary Table S2 online) followed by 21 fluorophore conjugates where necessary (streptavidin APC-A750, 15 min, 4 1C on ice). Cells were then washed and resuspended in 50 ml FACS buffer with 5 ml DAPI (4,6-diamidino-2-phenylindole) solution (1 mg ml À 1 , Sigma Aldrich, Saint Louis, MO) before analysis. Our FACS strategy has been previously described. 15 To examine mouse AM^s (see Supplementary Figure S1a Supplementary Table S5 online), washed, and resuspended in 100 ml FACS buffer, with 5 ml DAPI solution (1 mg ml À 1 , Sigma Aldrich) added before analysis. Critically, prior to each experiment, single-peak fluorescent calibration beads were used to maintain a standardized laser voltage for data acquisition (APC and APC-Cy7 fluorescence reference standards, Bangs Laboratories). To examine human AM^s (see Supplementary  Figure S1b All FACS data was acquired on a LSR-Fortessa (BD Biosciences, San Jose, CA) except Supplementary Figure S2 (LSR-Canto II, BD Biosciences), and X5,000 AM^events per sample was collected. Analysis was performed using the FlowJo software (Mac V8.7.3 or Windows V10, FlowJo LLC, Ashland, OR).
Statistics. All values are expressed as mean ± s.e.m. from at least two independent experiments. Unpaired two-tailed Student's t-test was performed for all studies comparing two sets of data, except where the s.d. of data sets differed and a Welch t-test was used. Studies comparing three sets of data were analyzed by the analysis of variance test followed by the Tukey's post-test for statistical significance. The correlation between human AMF CD11b and CD86 surface expression was determined by linear regression. Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software Inc, La Jolla, CA). and funded the study, interpreted all data, and edited the manuscript. All authors approved the final draft.
